Nutrigenomics and nutrigenetics in inflammatory bowel diseases

Journal of Clinical Gastroenterology

Volumn 46, Issue 9, 2012, Pages 735-747

  Gruber, Lisa ^a   Lichti, Pia ^a   Rath, Eva ^a   Haller, Dirk ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

diet; IBD; nutrients; nutrigenetics; nutrigenomics

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CATHELICIDIN; CYTOKINE; ICOSAPENTAENOIC ACID; IMMUNOMODULATING AGENT; IRON; LINOLEIC ACID; MULTIDRUG RESISTANCE PROTEIN 1; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROTEIN ZO1; RETINOID X RECEPTOR; ROSIGLITAZONE; SHORT CHAIN FATTY ACID; STAT PROTEIN; VITAMIN D; VITAMIN D RECEPTOR;

CARBOHYDRATE DIET; CARBOHYDRATE INTAKE; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; DIET; ENERGY RESOURCE; ENTERITIS; FAT INTAKE; FOOD COMPOSITION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENETICS; GENOTYPE; HUMAN; INTESTINE FLORA; LIPID DIET; MALNUTRITION; NONHUMAN; NUTRIENT; NUTRIGENETICS; NUTRIGENOMICS; NUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTAKE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

DIET; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; NUTRIGENOMICS;

EID: 84866261038     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31825ca21a     Document Type: Review

References (164)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. (Pubitemid 47123518)
2. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767-1773. (Pubitemid 36666773)
3. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407. (Pubitemid 44018812)
4. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
5. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
6. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517. (Pubitemid 38649869)
7. Korzenik JR. Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators. J Clin Gastroenterol. 2005;39(suppl 2):S59-S65. (Pubitemid 40397017)
8. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106:563-573.
9. Frank DN St, Amand AL, Feldman RA, et al. Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780-13785. (Pubitemid 350003397)
10. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205-211. (Pubitemid 43117279)
11. Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr Gastroenterol Rep. 2002;4:481-489.
12. Mutch DM, Wahli W, Williamson G. Nutrigenomics and nutrigenetics: the emerging faces of nutrition. FASEB J. 2005;19:1602-1616. (Pubitemid 41429518)
13. Filippi J, Al-Jaouni R, Wiroth JB, et al. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis. 2006;12:185-191.
14. Woolner J, Parker T, Kirby G, et al. The development and evaluation of a diet for maintaining remission in Crohn's disease. J Hum Nutr Diet. 1998;11:1-11. (Pubitemid 29188809)
15. Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease-epidemiology and treatment. Aliment Pharmacol Ther. 2009;30:99-112.
16. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007;1:CD000542.
17. Miller B, Fervers F, Rohbeck R, et al. Sugar consumption in patients with Crohn's disease. Verh Dtsch Ges Inn Med. 1976;82(pt 1):922-924.
18. Sonnenberg A. Geographic and temporal variations of sugar and margarine consumption in relation to Crohn's disease. Digestion. 1988;41:161-171. (Pubitemid 19048309)
19. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741-745. (Pubitemid 26126594)
20. Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology. 1992;3:47-52.
21. Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002;56:388-396. (Pubitemid 35232741)
22. Shores DR, Binion DG, Freeman BA, et al. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17: 2192-2204.
23. Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPARresponsive gene expression in a pig model of experimental IBD. Clin Nutr. 2006;25:454-465. (Pubitemid 43843028)
24. Roy N, BarnettM, Knoch B, et al. Nutrigenomics applied to an animal model of inflammatory bowel diseases: transcriptomic analysis of the effects of eicosapentaenoic acid- and arachidonic acid-enriched diets. Mutat Res. 2007;622:103-116. (Pubitemid 47224954)
25. Woodworth HL, McCaskey SJ, Duriancik DM, et al. Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res. 2010;70:7960-7969.
26. Suzuki T, Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab (Lond). 2010;7:19.
27. Hudert CA, Weylandt KH, Lu Y, et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA. 2006;103:11276-11281. (Pubitemid 44156509)
28. Tjonneland A, Overvad K, Bergmann MM, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut. 2009;58: 1606-1611.
29. de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis. Gastroenterology. 2010;139:1912-1917.
30. Jantchou P, Morois S, Clavel-Chapelon F, et al. Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study. Am J Gastroenterol. 2010;105: 2195-2201.
31. Geerling BJ, Dagnelie PC, Badart-Smook A, et al. Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol. 2000;95:1008-1013. (Pubitemid 30196738)
32. Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. J Parenter Enteral Nutr. 1997;21:357-365.
33. Thangaraju M, Cresci GA, Liu K, et al. GPR109A is a Gprotein- coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009;69:2826-2832.
34. Bugaut M. Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals. Comp Biochem Physiol B. 1987;86:439-472.
35. Venkatraman A, Ramakrishna BS, Shaji RV, et al. Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol. 2003;285:G177-G184. (Pubitemid 36736401)
36. Cresci GA, Thangaraju M, Mellinger JD, et al. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J Gastrointest Surg. 2010;14:449-461.
37. Tazoe H, Otomo Y, Karaki S, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res. 2009;30:149-156.
38. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.
39. Kanauchi O, Suga T, Tochihara M, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002;37(suppl 14):67-72. (Pubitemid 35385930)
40. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci. 1996; 41:2254-2259. (Pubitemid 26414449)
41. Treem WR, Ahsan N, Shoup M, et al. Fecal short-chain fatty acids in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18:159-164. (Pubitemid 24056473)
42. Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis. 2007;13: 1153-1164. (Pubitemid 47402601)
43. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114: 262-267. (Pubitemid 28093532)
44. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995; 102:448-455. (Pubitemid 26013210)
45. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996;38:365-375. (Pubitemid 26074316)
46. van der Waaij LA, Kroese FG, Visser A, et al. Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:669-674. (Pubitemid 38901635)
47. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. Highfat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137:1716-1724. e1-2.
48. Macfarlane S,Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther. 2006;24:701-714.
49. Langlands SJ, Hopkins MJ, Coleman N, et al. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut. 2004;53:1610-1616. (Pubitemid 39434104)
50. Hormannsperger G, Clavel T, Haller D. Gut matters: microbe-host interactions in allergic diseases. J Allergy Clin Immunol. 2012. [Epub ahead of print].
51. Koletzko S, Sherman P, Corey M, et al. Role of infant feeding practices in development of Crohn's disease in childhood. BMJ. 1989;298:1617-1618. (Pubitemid 19158541)
52. Rodriguez-Palmero M, Koletzko B, Kunz C, et al. Nutritional and biochemical properties of human milk: II. lipids, micronutrients, and bioactive factors. Clin Perinatol. 1999;26: 335-359. (Pubitemid 29288297)
53. Orrhage K, Nord CE. Factors controlling the bacterial colonization of the intestine in breastfed infants. Acta Paediatr Suppl. 1999;88:47-57. (Pubitemid 29489143)
54. Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007;56:661-667. (Pubitemid 46662932)
55. Leach ST, Mitchell HM, Eng WR, et al. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther. 2008;28:724-733.
56. Hunter JO. Is diet a factor in the pathogenesis of IBD? Inflamm Bowel Dis. 2008;14(suppl 2):S35-S36.
57. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507-1523. (Pubitemid 44915199)
58. Perl DP, Fogarty U, Harpaz N, et al. Bacterial-metal interactions: the potential role of aluminum and other trace elements in the etiology of Crohn's disease. Inflamm Bowel Dis. 2004;10:881-883. (Pubitemid 39545232)
59. Lerner AE, S. Perl D. Bacterial-aluminum interactions. The role of aluminum in bacterial-induced colitis in IL-10 deficient mice [abstract]. Gastroenterology. 2006;130:A362.
60. Werner T, Wagner SJ, Martinez I, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's diseaselike ileitis. Gut. 2011;60:325-333.
61. Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis. 2012;6:267-275.
62. Prescott NJ, Dominy KM, Kubo M, et al. Independent and population-specific association of risk variants at the IRGM locus with Crohn's disease. HumMol Genet. 2010;19:1828-1839.
63. Newman B, Siminovitch KA. Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol. 2005;21:401-407. (Pubitemid 40961164)
64. Cadwell K, Patel KK, Maloney NS, et al. Virus-plussusceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141:1135-1145.
65. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213-1222.
66. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001;167:1945-1953. (Pubitemid 32747499)
67. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut. 2000;47:211-214. (Pubitemid 30489764)
68. Naderi N, Farnood A, Habibi M, et al. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1816-1822.
69. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol. 2006;92:60-64. (Pubitemid 43831951)
70. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17:2386-2392. (Pubitemid 37542204)
71. Aoyagi Y, Nagata S, Kudo T, et al. Peroxisome proliferatoractivated receptor gamma 2 mutation may cause a subset of ulcerative colitis. Pediatr Int. 2010;52:729-734.
72. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134:688-695. (Pubitemid 351312727)
73. Hontecillas R, Horne WT, Climent M, et al. Immunoregulatory mechanisms of macrophage PPAR-gamma in mice with experimental inflammatory bowel disease. Mucosal Immunol. 2011;4:304-313.
74. Guri AJ, Mohapatra SK, Horne WT 2nd, et al. The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol. 2010;10:60.
75. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun. 2000;272:380-385. (Pubitemid 30444626)
76. Hontecillas R, Wannemeulher MJ, Zimmerman DR, et al. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr. 2002;132:2019-2027. (Pubitemid 34742894)
77. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004;127:777-791. (Pubitemid 39208411)
78. Wohlfert EA, Nichols FC, Nevius E, et al. Peroxisome proliferator- activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol. 2007;178:4129-4135. (Pubitemid 46492362)
79. Evans NP, Misyak SA, Schmelz EM, et al. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr. 2010;140:515-521.
80. Alonso L, Cuesta EP, Gilliland SE. Production of free conjugated linoleic acid by Lactobacillus acidophilus and Lactobacillus casei of human intestinal origin. J Dairy Sci. 2003;86:1941-1946. (Pubitemid 39067054)
81. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003;124:1265-1276. (Pubitemid 36531802)
82. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med. 2001;193:827-838. (Pubitemid 32524532)
83. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004;53:987-992. (Pubitemid 38824157)
84. Brand S, Staudinger T, Schnitzler F, et al. The role of Tolllike receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005;11:645-652. (Pubitemid 40965520)
85. Rigoli L, Romano C, Caruso RA, et al. Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2008;14:4454-4461.
86. Ferguson LR, Shelling AN, Browning BL, et al. Genes, diet and inflammatory bowel disease. Mutat Res. 2007;622:70-83. (Pubitemid 47214578)
87. Browning BL, Huebner C, Petermann I, et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with metaanalysis shows strong evidence for association. Am J Gastroenterol. 2007;102:2504-2512. (Pubitemid 47631777)
88. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003;73:1282-1292. (Pubitemid 38037422)
89. Glas J, Torok HP, Schiemann U, et al. MDR1 gene polymorphism in ulcerative colitis. Gastroenterology. 2004;126:367. (Pubitemid 38040750)
90. Palmieri O, Latiano A, Valvano R, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005;22:1129-1138. (Pubitemid 41779521)
91. Ardizzone S, Maconi G, Bianchi V, et al. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:516-523. (Pubitemid 46799634)
92. Huebner C, Browning BL, Petermann I, et al. Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm Bowel Dis. 2009;15:1784-1793.
93. Huebner C, Petermann I, Browning BL, et al. Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev. 2007;16: 1185-1192. (Pubitemid 46984957)
94. Annese V, Valvano MR, Palmieri O, et al. Multidrug resistance 1 gene in inflammatory bowel disease: a metaanalysis. World J Gastroenterol. 2006;12:3636-3644. (Pubitemid 43950939)
95. Onnie CM, Fisher SA, Pattni R, et al. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm Bowel Dis. 2006;12:263-271.
96. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733-5744. (Pubitemid 28519142)
97. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 2000;118:279-288. (Pubitemid 30067501)
98. Zhou S, Lim LY, Chowbay B. Herbal modulation of Pglycoprotein. Drug Metab Rev. 2004;36:57-104.
99. Nones K, Dommels YE, Martell S, et al. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br J Nutr. 2009;101:169-181.
100. Daniel H, Rubio-Aliaga I. An update on renal peptide transporters. Am J Physiol Renal Physiol. 2003;284:F885-F892. (Pubitemid 36443572)
101. Merlin D, Si-Tahar M, Sitaraman SV, et al. Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterology. 2001;120:1666-1679. (Pubitemid 32523485)
102. Buyse M, Tsocas A, Walker F, et al. PepT1-mediated fMLP transport induces intestinal inflammation in vivo. Am J Physiol Cell Physiol. 2002;283:C1795-C1800. (Pubitemid 35340612)
103. Zucchelli M, Torkvist L, Bresso F, et al. PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1562-1569.
104. Dalmasso G, Nguyen HT, Ingersoll SA, et al. The PepT1- NOD2 signaling pathway aggravates induced colitis in mice. Gastroenterology. 2011;141:1334-1345.
105. Marina-Garcia N, Franchi L, Kim YG, et al. Clathrin and dynamin-dependent endocytic pathway regulates muramyl dipeptide internalization and NOD2 activation. J Immunol. 2009;182:4321-4327.
106. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603. (Pubitemid 32531408)
107. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857. (Pubitemid 34259301)
108. Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA. 2009;106:15813-15818.
109. Biswas A, Liu YJ, Hao L, et al. Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum. Proc Natl Acad Sci USA. 2010;107:14739-14744.
110. Wehkamp J, Harder J,WeichenthalM, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004;53:1658-1664. (Pubitemid 39434112)
111. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2- dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731-734. (Pubitemid 40194644)
112. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010;16:90-97.
113. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol. 2010;11:55-62.
114. Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology. 2010;139:1630-1641. 1641 e1-2.
115. Fukushima K, Fiocchi C. Paradoxical decrease of mitochondrial DNA deletions in epithelial cells of active ulcerative colitis patients. Am J Physiol Gastrointest Liver Physiol. 2004;286:804-813.
116. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
117. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol. 2002;64:477-502. (Pubitemid 34259237)
118. Roediger WE, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br J Exp Pathol. 1986;67:773-782. (Pubitemid 17212913)
119. Shekhawat PS, Srinivas SR, Matern D, et al. Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007;92:315-324. (Pubitemid 350123730)
120. Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980;2:712-715. (Pubitemid 10060060)
121. Den Hond E, Hiele M, Evenepoel P, et al. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology. 1998;115:584-590. (Pubitemid 28397293)
122. Ahmad MS, Krishnan S, Ramakrishna BS, et al. Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut. 2000;46:493-499. (Pubitemid 30305813)
123. Thibault R, De Coppet P, Daly K, et al. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology. 2007;133:1916-1927. (Pubitemid 350180798)
124. Ritzhaupt A, Wood IS, Ellis A, et al. Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. J Physiol. 1998;513(pt 3):719-732. (Pubitemid 29008104)
125. Werner T, Haller D. Intestinal epithelial cell signalling and chronic inflammation: from the proteome to specific molecular mechanisms. Mutat Res. 2007;622:42-57. (Pubitemid 47211180)
126. Warner EE, Dieckgraefe BK. Application of genome-wide gene expression profiling by high-density DNA arrays to the treatment and study of inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:140-157. (Pubitemid 34213514)
127. Lin HM, Helsby NA, Rowan DD, et al. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:1021-1029.
128. Rezzi S, Ramadan Z, Fay LB, et al. Nutritional metabonomics: applications and perspectives. J Proteome Res. 2007; 6:513-525. (Pubitemid 46340155)
129. te Velde AA, de Kort F, Sterrenburg E, et al. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:325-330. (Pubitemid 46465914)
130. Martinez-Augustin O, Merlos M, Zarzuelo A, et al. Disturbances in metabolic, transport and structural genes in experimental colonic inflammation in the rat: a longitudinal genomic analysis. BMC Genomics. 2008;9:490.
131. Costello CM, Mah N, Hasler R, et al. Dissection of the inflammatory bowel disease transcriptome using genomewide cDNA microarrays. PLoS Med. 2005;2:e199.
132. Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13:807-821. (Pubitemid 47203859)
133. von Stein P, Lofberg R, Kuznetsov NV, et al. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology. 2008;134:1869-1881; quiz 2153-2154. (Pubitemid 351790741)
134. Fang K, Zhang S, Glawe J, et al. Temporal genome expression profile analysis during t-cell-mediated colitis: identification of novel targets and pathways. Inflamm Bowel Dis. 2011.
135. Barnett MP, McNabb WC, Cookson AL, et al. Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species. BMC Immunol. 2010;11:39.
136. Dooley TP, Curto EV, Reddy SP, et al. Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. Inflamm Bowel Dis. 2004;10:1-14. (Pubitemid 38072439)
137. Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis. 2009;15:616-629.
138. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433. (Pubitemid 46469959)
139. Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solidphase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom. 2007;21:4142-4148.
140. Shkoda A, Werner T, Daniel H, et al. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res. 2007;6: 1114-1125. (Pubitemid 46480475)
141. Werner T, Shkoda A, Haller D. Intestinal epithelial cell proteome in IL-10 deficient mice and IL-10 receptor reconstituted epithelial cells: impact on chronic inflammation. J Proteome Res. 2007;6:3691-3704. (Pubitemid 47522758)
142. Werner T, Hoermannsperger G, Schuemann K, et al. Intestinal epithelial cell proteome from wild-type and TNFDeltaARE/WT mice: effect of iron on the development of chronic ileitis. J Proteome Res. 2009;8:3252-3264.
143. Wittwer J, Rubio-Aliaga I, Hoeft B, et al. Nutrigenomics in human intervention studies: current status, lessons learned and future perspectives. Mol Nutr Food Res. 2011;55: 341-358.
144. M'Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis. 2011;17:875-883.
145. Berndt U, Bartsch S, Philipsen L, et al. Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol. 2007;179:295-304. (Pubitemid 46986545)
146. Knoch B, Barnett MP, Cooney J, et al. Dietary oleic acid as a control fatty acid for polyunsaturated fatty acid intervention studies: a transcriptomics and proteomics investigation using interleukin-10 gene-deficient mice. Biotechnol J. 2010;5: 1226-1240.
147. Cooney JM, Barnett MP, Brewster D, et al. Proteomic analysis of colontTissue from interleukin-10 gene-deficient mice fed polyunsaturated fatty acids with comparison to transcriptomic analysis. J Proteome Res. 2012;11:1065-1077.
148. Shkoda A, Ruiz PA, Daniel H, et al. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology. 2007;132: 190-207. (Pubitemid 46108743)
149. Nicholson JK, Lindon JC, Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29: 1181-1189.
150. Nicholson JK, Wilson ID. Opinion: understanding "global" systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003;2:668-676. (Pubitemid 37361770)
151. Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 2004;9:1-31. (Pubitemid 38660013)
152. Bezabeh T, Somorjai RL, Smith IC, et al. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. Am J Gastroenterol. 2001;96:442-448.
153. Balasubramanian K, Kumar S, Singh RR, et al. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn Reson Imaging. 2009;27:79-86.
154. Bjerrum JT, Nielsen OH, Hao F, et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res. 2010;9: 954-962.
155. Sharma U, Singh RR, Ahuja V, et al. Similarity in the metabolic profile in macroscopically involved and uninvolved colonic mucosa in patients with inflammatory bowel disease: an in vitro proton ((1)H) MR spectroscopy study. Magn Reson Imaging. 2010;28:1022-1029.
156. Williams HR, Cox IJ, Walker DG, et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol. 2009;104:1435-1444.
157. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546-551. (Pubitemid 46340158)
158. Bezabeh T, Somorjai RL, Smith IC. MR metabolomics of fecal extracts: applications in the study of bowel diseases. Magn Reson Chem. 2009;47(suppl 1):S54-S61.
159. Martin FP, Rezzi S, Philippe D, et al. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res. 2009;8:2376-2387.
160. Shiomi Y, Nishiumi S, Ooi M, et al. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis. 2011;17:2261-2274.
161. Schicho R, Nazyrova A, Shaykhutdinov R, et al. Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by (1)H NMR spectroscopy. J Proteome Res. 2010;9:6265-6273.
162. Baur P, Martin FP, Gruber L, et al. Metabolic phenotyping of the Crohn's disease-like IBD etiopathology in the TNF(DeltaARE/WT) mouse model. J Proteome Res. 2011; 10:5523-5535.
163. Jansson J,Willing B, LucioM, et al.Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One. 2009;4:e6386.
164. Lin HM, Edmunds SJ, Zhu S, et al. Metabolomic analysis reveals differences in urinary excretion of kiwifruit-derived metabolites in a mouse model of inflammatory bowel disease. Mol Nutr Food Res. 2011;55:1900-1904.